Shagun Bindlish, MD, board member of the American Diabetes Association, discusses challenges to diagnosing and treating venous disease in patients with obesity.

William Schaffner, MD, a long-time liaison from the NFID to the ACIP working groups, is concerned about fragmentation of US vaccine recommendations.

The FDA's ODD award is based on the positive findings from the phase 2 TouCAHn trial, which also support Crinetics' robust phase 3 pivotal clinical trial program for the novel agent.

Vaginal estradiol is often prescribed as first-line therapy for genitourinary syndrome of menopause, making the findings supportive of current clinical practice.

A Cleveland Clinic trial revealed that AI-driven precision treatment significantly reduced HbA1c and body weight, often eliminating need for medications other than metformin.

Your daily dose of the clinical news you may have missed.

The risk for MDD is greatest in the first month after diagnosis and the absolute risk remains elevated even 20 years later, making early detection and treatment imperative.

The first oral penem antibiotic, Orlynvah™, has launched in the US, offering a vital treatment option for women with resistant uncomplicated UTIs.

This week’s roundup covers nutrition counseling barriers, tau pathology in mood disorders, RSV protection, AD patient needs, and a new Shingrix syringe.

William Schaffner, MD, advises first and foremost to stay away from politics, to acknowledge and normalize patient fear and concern, and to answer quickly and with confidence.